For decades, multinationals treated China primarily as either a vast growth market or a rising competitive threat. But as growth slows, com...

India's regulatory hurdles slow down early-stage drug trials significantly. This complexity causes Indian companies to conduct crucial firs...

2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

The Union Budget is making a significant investment in India's health and innovation. Biopharma has been identified as a key strategic sect...

India's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...

The proposed fund aims to position India as a global biopharma manufacturing hub

The joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...

Proceeds from the IPO will be used towards investment in Mobius Biomedical Inc, acquisition of licenses for product development of skincare...

NITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...

Ahead of the 14th edition of the annual BioPharma and Healthcare Summit, that bring stakeholders from India and the United States on one pl...

India's health and innovative and biopharma sector deserves better attention from the government to help realise its full potential

The Bengaluru-based company has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the correspo...

The McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...

"India offers several advantages in R&D, but it's behind," said Bart Janssens, a BCG partner and coauthor of the report.

Emerging markets will drive 70% of growth in the pharma industry and India will require supportive policies to leverage the BioPharma.